Efficacy and Tolerability of Oral Desloratadine (10mg OD), Rupatadine (10mg OD) and Ketotifen (1mg BD) in Seasonal Allergic Rhinitis: A Prospective Randomized Study
International Journal of Current Pharmaceutical Review and Research · 30.07.2026 · 18 (07)
DOI: 10.25258/ijcpr.18.7.65 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Current Pharmaceutical Review and Research, online erschienen am 30.07.2026. Verfasst von Chitranjan Kumar und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Rhinitis is an inflammation of the nasal mucosa that typically manifests as sneezing, runny, or blocked noses. The frequency of allergic rhinitis is higher than that of non-allergic rhinitis. Treatment for SAR is primarily based on antihistamines. The antihistamines that are most frequently administered in our area are desloratadine, rupatadine, and ketotifen. In this study, the effectiveness and tolerability of rupatadine, ketotifen, and desloratadine in SAR were compared.
Methods
From August 2025 to January 2026, a prospective, randomized, three-arm, open-label comparison trial of desloratadine, rupatadine, and ketotifen in SAR was carried out at the Department of ENT, ANMMCH, Gayaji, and Bihar. TNSS was used to gauge the patients' quality of life and the severity of their SAR symptoms. At every visit, adverse effects were tracked during the clinical examination. Desloratadine (DES), rupatadine (RUP), and ketotifen (KET) were the three groups into which study participants were systematically randomized. Oral doses of desloratadine (10 mg OD), rupatadine (10 mg OD), and ketotifen (1 mg BD) were administered according to the designated group. Every drug was administered for four weeks. Every patient had a weekly follow-up during the four-week course of treatment. Change in the mean TNSS from baseline was the primary outcome measure. Individual nasal symptom scores, quality of life, and study medication tolerability were the supplementary outcome measures.
Results
For this study, a total of 150 patients were enrolled and split into three groups. When it came to improving rhinorrhea, nasal congestion, TNSS, and AEC, DES and RUP were equally effective but considerably superior to KET (p=0.05). In terms of improving sneezing, nasal irritation, and quality of life, all medications were similarly beneficial, with no statistically significant intergroup difference. Because there were slightly fewer adverse events overall, RUP seemed to have greater tolerance.
Conclusion
Compared to KET, DES and RUP are more efficient and act more quickly. There were only a few minor, self-limiting, brief side effects that didn't require medical attention, and all of the research drugs were well tolerated.
Zitieren
APA
Kumar, C., Sandhya, S., & Kumar, U. (2026). Efficacy and Tolerability of Oral Desloratadine (10mg OD), Rupatadine (10mg OD) and Ketotifen (1mg BD) in Seasonal Allergic Rhinitis: A Prospective Randomized Study. International Journal of Current Pharmaceutical Review and Research, 18(07). https://doi.org/10.25258/ijcpr.18.7.65
Vancouver
Kumar C, Sandhya S, Kumar U. Efficacy and Tolerability of Oral Desloratadine (10mg OD), Rupatadine (10mg OD) and Ketotifen (1mg BD) in Seasonal Allergic Rhinitis: A Prospective Randomized Study. International Journal of Current Pharmaceutical Review and Research. 2026;18(07). doi:10.25258/ijcpr.18.7.65
BibTeX
@article{Kumar2026,
author = {Kumar, Chitranjan and Sandhya, Sandhya and Kumar, Umesh},
title = {Efficacy and Tolerability of Oral Desloratadine (10mg OD), Rupatadine (10mg OD) and Ketotifen (1mg BD) in Seasonal Allergic Rhinitis: A Prospective Randomized Study},
journal = {International Journal of Current Pharmaceutical Review and Research},
year = {2026},
volume = {18},
number = {07},
doi = {10.25258/ijcpr.18.7.65}
}
EUVIMED